Cannabics Pharmaceuticals Inc (OTCMKTS: CNBX) has announced a new website and logo. Additionally, the company has a new corporate presentation on its website.
Updates mark a shift from a preclinical to the clinical-stage company
The updates align with its change from a pre-clinical to a clinical-stage corporation that focuses on complying with FDA regulations.
The new site has updated information on Cannabics’ drug candidates and their clinical path. It also offers the latest news for investors, such as SEC filings, press releases, and company presentations.
Cannabics is a company that deals with the discovery, development, and commercialization of cannabinoid medicines and technologies for the treatment of cancer. Its research and development facility is located in Israel. It has a license from the Ministry of Health that permits them to conduct clinical research on cannabinoids formulations for cancer.
The company, previously known as American Mining Corporation, has researched the effects of cannabinoid formulation on cancer tumors since it started in 2012. The company, which is a subsidiary of Cannabics Inc, changed its name in 2014. Cannabis uses advanced methodologies to determine the physiological effects different cannabinoids have in tumors.
Drugs cannabis is currently developing
Recently, Cannabics has been focused on RCC-33, an oral capsule to treat colorectal cancer. RCC consists of a high concentration of cannabinoids such as cannabigerolic acid (CBGA) and cannabidivarin (CBDV).
Cannabics recently conducted a trial that infected mice with human colorectal cancer to test the drug’s efficacy. The results showed a survival rate of 31 days after the administration of RCC-33 compared to 23 days in mice in the control group. This was a 35% prolonged survival rate.
Cannabics Pharmaceuticals is planning a meeting with the U.S Food and Drug Administration (FDA) to discuss a pre-IND which will allow it to start Phase 1 and 2a trials by 2022.
It is also working on the development of Cannabics SR, an oral lipid capsule that consists of a standardized formulation of cannabinoids to treat cancer anorexia-cachexia syndrome. Another drug the company is working on is Cannabics CDx which gets drug sensitivity for cannabinoid cancer therapy.
The company has a goal to develop therapies that meet the particular need of individual cancer patients.
CV Sciences Inc. (OTCMKTS: CVSI) Reports 8% Drop In Sales In Q3 2021 Attributable To Regulatory Uncertainty in CBD
Post Views: 7 CV Sciences Inc. (OTCMKTS: CVSI) has announced its third-quarter 2021 financial results for the period ending September...
AuxlyCannabis Group Inc. (OTCMKTS: CBWTF) Reports Net Revenue Growth 95% In Q3 2021
Post Views: 45 Auxly Cannabis Group Inc. (OTCMKTS: CBWTF) has announced its financial results for the third quarter and nine...
Vivo Cannabis Inc. (OTCMKTS: VVCIF) Releases Q3 2021 Net Revenue of $6.2 Million as It Expands Internationally
Post Views: 31 Vivo Cannabis Inc. (OTCMKTS: VVCIF) has released its Q3 2021 operating and financial results for the quarter...
Rubicon Organics Inc. (OTCMKTS: ROMJF) Announces 124% YoY Growth In Revenue in Q3 2021 After Launching New Brands
Post Views: 11 Rubicon Organics Inc. (OTCMKTS: ROMJF) has released its Q3 2021 results ending September 30, 2021, in which...
Sugarbud Craft Growers Corp (OTCMKTS: SBUDF) Reports 120% Sequential Revenue Growth in Q3 2021
Post Views: 14 Sugarbud Craft Growers Corp (OTCMKTS: SBUDF) has filed its unaudited consolidated preliminary financial statements for the quarter...
Indiva Limited (OTCMKTS: NDAF) Reports 143% YoY increase in Revenue In Q3 2021
Post Views: 46 Indiva Limited (OTCMKTS: NDAF) has announced its operating and financial results for the third quarter ending September...